China’s Rise in Drug Development Looms Over U.S.
Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is ...
Frank Hayden, Who Led Global Growth of the Special Olympics, Dies at 96
His research showing the positive effects of athletics on intellectually disabled children led Eunice Kennedy Shriver to ask him to help sta...
Court in Kenya Suspends Plans for U.S. Ebola Quarantine Unit
The order came after U.S. officials said that a 50-bed facility was being established in the African country to house American citizens expo...
Suit Says Black Infants Were Subjected to Experimental Vaccine Without Consent
The babies were part of a vaccine trial for a respiratory virus in the 1960s and died shortly after. Their families said they had been unawa...
Genetic Scores are Booming. But Will Anti-Discrimination Laws Cover Your DNA?
As predictive medicine advances, legal scholars warn that decades-old federal guidelines could set up a potential clash between your genes a...
KFF’s Chief Executive to Retire
Drew Altman, who transformed KFF from a little-known family foundation to a major source of U.S. health policy research, will step down at t...
The Viruses Causing New Outbreaks Are Much Less Familiar to Science
The types of Ebola and hantavirus panicking officials are very different from the species identified decades ago, raising new questions abou...
Trump Administration to Send Americans Exposed to Ebola to Kenya
In past outbreaks, Americans exposed to the virus were sent home to be treated in state-of-the-art facilities. The Trump administration has ...
Eli Lilly to Buy 3 Vaccine Developers
The drugmaker said it would spend up to $4 billion to acquire small companies exploring vaccines for shingles, Epstein-Barr virus and other ...
A Powerful H.I.V. Drug Lands in Zambia. But Will It Reach Those Who Need It?
Lenacapavir, which protects people from H.I.V. infection with twice-yearly shots, is arriving in a country where the health system has been ...
Subscribe to:
Posts
(
Atom
)
